What Cannabis Inhalers Can (and Cannot) Do

For people who use medical cannabis but want to avoid smoking, a metered-dose inhaler may offer a more controlled way to deliver THC or other cannabis compounds. These devices are designed to produce a measured aerosol for inhalation. They are not the same as asthma inhalers, however, and cannabis inhalers should not be used to treat wheezing, an asthma attack, or another breathing emergency.

One of the better-studied examples is the Syqe Inhaler, examined in a randomized, placebo-controlled trial of 27 adults with chronic neuropathic pain and complex regional pain syndrome. Participants received single inhaled doses of either 0.5 milligrams or 1 milligram of THC. THC appeared in the bloodstream within minutes, and the 1-milligram dose reduced pain more than placebo during the study period. Reported adverse effects were generally mild, but the trial was small and evaluated single doses rather than long-term treatment. Read the full clinical trial on the metered-dose cannabis inhaler.

How cannabis inhalers work

Unlike smoked cannabis, a medical inhaler can be engineered to deliver a predetermined amount of aerosol with each actuation. That may make dose tracking easier than estimating the amount absorbed from a joint or conventional vaporizer. Inhaled cannabinoids also tend to take effect faster than oral products, which must pass through the digestive system before producing their full effects.

Research on specialized devices has measured rapid absorption and dose-related blood levels of THC. But the performance of one pharmaceutical-style inhaler cannot automatically be applied to every cannabis vape pen, nebulizer, or inhaled product sold through a dispensary. Device design, cannabis formulation, particle size, temperature, inhalation technique, and labeling can all affect the dose a person receives.

Inhalation also is not risk-free. The U.S. Centers for Disease Control and Prevention notes that cannabis smoke can damage lung tissue and contains many of the same toxins and irritants found in tobacco smoke. Cannabis vaping products have also been associated with serious lung injuries, particularly products containing vitamin E acetate during the 2019 outbreak. See the CDC’s overview of cannabis and lung health.

They are not bronchodilators

The original description of cannabis inhalers as bronchodilators is misleading. A bronchodilator is a medicine specifically developed to relax airway muscles and improve airflow. A cannabis inhaler is a drug-delivery device; it does not replace albuterol or another prescribed rescue inhaler, and inhaled cannabis should never be relied on during an asthma attack or other breathing crisis.

People with asthma, COPD, chronic cough, or other lung disease should discuss any inhaled cannabis product with a qualified clinician before using it. An aerosol may irritate the airways, and avoiding smoke does not establish that a particular inhaled cannabis product is safe for someone with respiratory disease. Anyone experiencing severe shortness of breath should seek emergency medical care rather than trying cannabis.

What about CBD inhalers?

Evidence for CBD inhalers is much more limited than one might assume. Studies of CBD in other forms do not prove that an inhaled CBD product can treat inflammation, anxiety, chronic pain, nausea, insulin needs, weight, or seizures. Claims about those benefits should be evaluated product by product and condition by condition.

In the United States, the FDA-approved cannabis-derived medicine is oral cannabidiol, marketed as Epidiolex. It is approved for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in eligible patients; it is not an inhaler and is not a general treatment for every seizure disorder. View the FDA prescribing information for Epidiolex.

The same distinction applies to CannatolRx Rescue, which is described by its manufacturer as a cannabinoid-and-terpene nasal spray for acute seizure treatment. The company states that the product is not FDA approved and that it is still gathering preclinical data and planning clinical research. A patent or marketing claim is not evidence that a product safely stops seizures. It should not replace an individualized seizure-rescue plan prescribed by a neurologist. Review the manufacturer’s information about CannatolRx’s regulatory status.

Questions to ask before using one

Anyone considering a cannabis inhaler should ask a clinician or pharmacist:

• What active ingredients and dose are delivered with each use?
• Has the specific device and formulation been tested in people?
• Could it interact with prescription medicines or worsen an existing condition?
• What symptoms require stopping the product and seeking care?
• What non-inhaled alternatives might provide similar relief?

Specialized cannabis inhalers may offer rapid delivery and more precise dosing than smoking, but the evidence remains limited and device-specific. They are not asthma medicines, not automatically safer for people with lung disease, and not a substitute for established seizure treatments. A healthcare professional can help determine whether an inhaled product is appropriate and how it fits into a safer, evidence-based treatment plan.